drug:wegovy

Less for Less: CVS drops Zepbound for Wegovy

CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).

GLP1.Guide Staff

GLP1.Guide Staff

— 1 min read
Less for Less: CVS drops Zepbound for Wegovy

CVS Health is the closest pharmacy for many people in the US, and they have been one of the main points by which GLP1 Receptor Agonists can be accessed – a trusted name in the retail pharmaceutical business.

🍃
Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

Disappointingly, CVS Health has dropped the more effective Zepbound (Tirzepatide) for less effective Wegovy (Semaglutide) and Saxenda (Liraglutide).

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
AP NewsTOM MURPHY

The Associated Press article puts it charitably (a "coverage challenge"), but this seems like an absolute step away from the simple goal of effective patient care.

To be fair, they made this decision before the results of the SURMOUNT-5 trial which was a direct head to head comparison between Tirzepatide and Semaglutide. Check out the links below...

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:

Read the rest on Substack

Read more